Nume: Etelcalcetidă
CAS Nr. : 1262780-97-1
Secvenţă: Disulfură de N-acetil-D-cisteinil-D-alanil-D-arginil-D-arginil-D-arginil-D-alanil-D-argininamidă cu clorhidrat de L-cisteină
Formulă moleculară: C38H74ClN21O10S2
Greutate moleculară : 1084.71
Puritate: >98.0%
Sursă: sintetic
Etelcalcetida este un receptor calcimimetic și sensibil la calciu (CaSR) agonist composed of a synthetic peptide comprised of seven D-amino acids that can be used to treat secondary hyperparathyroidism (sHPT) in hemodialysis patients with chronic kidney disease (CKD). Upon intravenous administration, etelcalcetide mimics calcium and allosterically binds to and activates the CaSR expressed by the parathyroid gland. Acest lucru suprimă sinteza și secreția hormonului paratiroidian (PTH), reducând astfel nivelul de PTH și scăzând nivelurile serice de calciu și fosfor. PTH crescut este adesea observat la pacienții cu CKD și este asociat cu homeostazia dereglată calciu-fosfat..
Etelcalcetidă (formerly velcalcetide, trade name Parsabiv) is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. It is administered intravenously at the end of each dialysis session.Etelcalcetide functions by binding to and activating the calcium-sensing receptor in the parathyroid gland. Parsabiv is currently owned by Amgen and Ono Pharmaceuticals in Japan.
Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017.
